A Drug Cocktail of Rapamycin, Acarbose, and Phenylbutyrate Enhances Resilience to an Early-Stage Model of Alzheimer’s Disease

Abstract

The process of aging is defined by the breakdown of critical maintenance pathways leading to an accumulation of damage and its associated phenotypes. Aging affects many systems and is considered the greatest risk factor for a number of diseases. Therefore, interventions aimed at establishing resilience to aging should delay or prevent the onset of age-related diseases. Recent studies have shown a three-drug cocktail consisting of rapamycin, acarbose, and phenylbutyrate delayed the onset of physical, cognitive, and biological aging phenotypes in old mice. To test the ability of this drug cocktail to impact Alzheimer’s disease (AD), an Adeno-Associated-Viral vector model of AD was created. Mice were fed the cocktail 2 months prior to injection and allowed 3 months for phenotypic development. Cognitive phenotypes were evaluated through a navigation learning task. To quantify neuropathology, immunohistochemistry was performed for AD proteins and pathways of aging. Age related lesions in the brain were evaluated through a geropathology grading platform. Results suggested the drug cocktail was able to increase resilience to cognitive impairment, inflammation, age-related lesions, and AD protein aggregation while enhancing autophagy and synaptic integrity, preferentially in female cohorts. In conclusion, female mice were more susceptible to the development of early stage AD neuropathology and learning impairment, and more responsive to treatment with the drug cocktail in comparison to male mice. Translationally, a model of AD where females are more susceptible would have greater value as women have a greater burden and incidence of disease compared to men. These findings validate past results and provide the rationale for further investigations into enhancing resilience to early-stage AD by enhancing resilience to aging.